Vistagen is a clinical-stage therapeutics company developing intranasal pherine product candidates—drugs that activate peripheral nasal chemosensory neurons to modulate brain circuits—targeting neuropsychiatric and neurological conditions including social anxiety disorder, major depressive disorder, vasomotor symptoms, mental fatigue, and cancer cachexia. The company's lead candidate, fasedienol, is in late-stage clinical development for acute anxiety treatment designed for as-needed use with rapid onset and a favorable safety profile compared to existing medications. Vistagen generates value through the advancement of its patent-protected pipeline toward regulatory approval and commercialization, supported by partnerships in key international markets and a lean operational model utilizing contract organizations for development and manufacturing.